1. The utilisation of drugs (medicines) is reflected and described in the
Pharmaceutical Consumption Statistics.
JAMASOFT2017

2. There is a link (causal feedback) (statistically significant and positive relationship)
Between
the level of pharmaceutical consumption
and health statistics (life expectancy).
JAMASOFT2017

3. Using Drug Consumption Data Estimate of Disease Prevalence
JAMASOFT2017

4. Pharmaceutical consumption by DDDs.
according to the
Anatomical Therapeutic Chemical
Classification
ATC/Defined Daily Dose (DDD)
system
JAMASOFT2017

5. Definition
Defined daily dose (DDD) is defined as the assumed average maintenance dose per day for a drug used on its main indication in adults.
JAMASOFT2017

6. DDDs are assigned to each active ingredient(s) in a given therapeutic class by International Expert Consensus.
For instance,
the DDD for oral aspirin equals 3 grams, which is the assumed maintenance daily dose to treat pain in adults.
DDDs do not necessarily reflect the average daily dose actually used in a given country.
DDDs can be aggregated within and across therapeutic classes of the Anatomical Therapeutic Chemical Classification (ATC).
JAMASOFT2017

7. The consumption of pharmaceuticals
is increasing across OECD countries not only in terms of expenditure but also in terms of volume (or quantity) of drugs consumed.
One of the factors contributing to the rise in pharmaceutical consumption is the ageing of the population, which leads to growing demand for drugs to treat or at least control different ageing-related diseases.
JAMASOFT2017

8. The trend rise
in pharmaceutical consumption is also observed in countries where
the population ageing process is less advanced, indicating that other factors
such as physicians’ prescription habits
or the degree of cost-sharing with patients
also play a role.
JAMASOFT2017

9. Pharmaceutical consumption
has a positive and statistically significant effect on remaining life expectancy at age 40 and 60 years, although the effect on life expectancy at birth is small and not significant.
JAMASOFT2017

10. JAMASOFT2017

11. JAMASOFT2017

12. JAMASOFT2017

13. JAMASOFT2017

14. IMS Health
is the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries.
JAMASOFT2017

15. of the company was Intercontinental Medical Statistics
The original name
of the company was Intercontinental Medical Statistics
JAMASOFT2017

16. IMS
was founded in 1954.
JAMASOFT2017

17. IMS is a healthcare informatics organization
with
a global presence
in over 100 countries.
JAMASOFT2017

18. IMS Health
serves leading decision makers in health care, including pharmaceutical manufacturers and distributors, providers, payers, government agencies, policymakers, researchers and the financial community.
JAMASOFT2017

19. trends and perspectives
IMS applies
leading-edge technologies to transform billions of pharmaceutical transactions collected from thousands of sources into strategic insights.
Interpreted and analyzed by IMS experts, these insights are an unmatched source of
trends and perspectives
about the pharmaceutical marketplace – precise market intelligence that can be translated into action.
JAMASOFT2017

20. Virtually every major pharmaceutical company
is a client of IMS along with professional services firms, the financial community, government and regulatory agencies, and agencies, researchers and educators.
JAMASOFT2017

21. IMS tracks over 1 million pharmaceutical products,
capturing 70% of all prescriptions worldwide and also provides market research and consulting services to the healthcare industry.
JAMASOFT2017

22. In addition
to its presence as a global leader of knowledge regarding pharmaceutical products, IMS also has extensive patient and physician-level data to examine health care utilization and expenditures.
JAMASOFT2017

23. The company draws
on its global technology infrastructure and unique combination of in-depth, sophisticated analytics, on-shore and off-shore commercial services, and consulting platforms to help clients better understand the performance and value of medicines.
JAMASOFT2017

24. Data Sources
IMS processes billions of healthcare transactions each year, covering every major world market. The company receives data from more than 139,000 data suppliers covering 730,000 individual dispensing sites, worldwide.
JAMASOFT2017

25. Data sources include drug manufacturers, wholesalers,
retail pharmacies,
hospitals,
long-term care facilities
and healthcare professionals.
JAMASOFT2017

26. The world’s largest pharmaceutical databases provide a view into:
Physician prescribing patterns and brand preferences,
Healthcare classes of trade, including hospitals, pharmacies, physicians’ offices, nursing homes and alternate care sites,
Benchmarks and measurements within therapeutic categories,
Prescription drugs and third-party reimbursement profiles,
Profiles and trends of diagnoses, best practices, and treatment patterns,
Promotional campaign mix and effectiveness in the professional and consumer areas,
Modeling, measuring and benchmarking techniques for the ambulatory treatment area,
Global healthcare issues.
JAMASOFT2017

27. High priority areas include:
- Drug Utilization Trends and Expenditures,
Analysis of national trends in prescription drug utilization and office-based care,
Examination of adoption of new therapies among patient and physician subpopulations,
Evaluation of prescription use and expenditures and factors that influence these trends.
JAMASOFT2017

28. Moreover:
• Geographic Variations in Care Examination of geographic variations in treatments, costs and outcomes
Ecologic studies examining how geographic variation in prescription use (e.g., antibiotics) is associated with specific outcomes (e.g., antimicrobial resistance) is reflected.
JAMASOFT2017

29. Moreover: • Real-world practice
Analysis of association between patient, physician, and health system characteristics and practice patterns
Establishment of best practices and quality metrics for specific conditions or populations, including for preventive care and screening
Utilization trends and costs in specific medical areas, such as oncology, cardiovascular disease or rare diseases where orphan drugs or specialty drugs are used,
Investigations of socioeconomic, racial, or ethnic disparities in processes or outcomes of care.
JAMASOFT2017

30. IMS DATA ASSETS
Some of IMS Health’s core assets are described below. Other data are also available to address a broad range of research questions (e.g., information on drug development; data examining specialty and biologic therapies; electronic medical record data). Access further information about key IMS data assets by visiting the website.
JAMASOFT2017

31. IMS DATA ASSET
National Prescription Audit™ Provides weekly and monthly analyses of prescription activity for all products, reflecting what the pharmacist dispenses to the consumer, stratification by some patient and physician characteristics possible.
JAMASOFT2017

32. Xponent™
Provides comprehensive prescriber data based on actual prescription activity within the retail, mail service, long-term care, and specialty retail markets, projects prescriptions generated across all prescription channels, payment types (cash) and product level for more than 800,000 prescribers monthly .
JAMASOFT2017

33. National Disease and Therapeutic Index™
Provides data from nationally representative audit of office-based physicians; focus on patterns of treatment and disease.
JAMASOFT2017

34. Supporting the Lifecycle of Medicinal Products
IMS stands ready to help throughout the development life cycle — from the assessment of market potential in pre-launch stages through the intricacies of product launch and, finally, through that transition period when clients must consider new options for products long on the market.
JAMASOFT2017

35. JAMASOFT2017

36. There are a lot of variations
across countries in the consumption of drugs for the treatment.
JAMASOFT2017

37. The consumption of antibiotics varies from a low of 9 DDDs per people per day in Switzerland to a high of 32 in Greece.
JAMASOFT2017

38. As over-consumption of antibiotics
has been acknowledged to create bacterial resistance, many countries have launched in recent years information campaigns targeting physicians and/or patients in order to reduce antibiotic consumption. As a result, consumption has stabilised in many countries and even decreased in some others (such as France, -Portugal and the Slovak Republic). By contrast, -consumption has risen between 2000 and 2007 in -countries that had below-average initial levels of -consumption (such as Denmark and Ireland).
JAMASOFT2017

39. Thanks for your attention.
JAMASOFT2017